[go: up one dir, main page]

CO2018002703A2 - Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos - Google Patents

Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos

Info

Publication number
CO2018002703A2
CO2018002703A2 CONC2018/0002703A CO2018002703A CO2018002703A2 CO 2018002703 A2 CO2018002703 A2 CO 2018002703A2 CO 2018002703 A CO2018002703 A CO 2018002703A CO 2018002703 A2 CO2018002703 A2 CO 2018002703A2
Authority
CO
Colombia
Prior art keywords
antibodies
promiostatin
latent myostatin
myostatin antibodies
myostatin
Prior art date
Application number
CONC2018/0002703A
Other languages
English (en)
Inventor
Michelle Straub
Adriana Donovan
Katherine Jane Turner
Gregory J Carven
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of CO2018002703A2 publication Critical patent/CO2018002703A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)

Abstract

La presente divulgación se refiere a anticuerpos que se unen específicamente a la proMiostatina y/o Miostatina latente, incluyendo anticuerpos que son moduladores de la actividad y/o biología de la miostatina, composiciones farmacéuticas que los contienen, ácidos nucleicos que codifican estos anticuerpos, y células aisladas que comprenden estos ácidos nucleicos.
CONC2018/0002703A 2015-09-15 2018-03-14 Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos CO2018002703A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562219094P 2015-09-15 2015-09-15
PCT/US2016/052014 WO2017049011A1 (en) 2015-09-15 2016-09-15 Anti-pro/latent-myostatin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CO2018002703A2 true CO2018002703A2 (es) 2018-11-22

Family

ID=57043000

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0002703A CO2018002703A2 (es) 2015-09-15 2018-03-14 Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos

Country Status (25)

Country Link
US (3) US10751413B2 (es)
EP (3) EP4461312A3 (es)
JP (3) JP7107836B2 (es)
KR (3) KR20250033313A (es)
CN (4) CN113912718B (es)
AU (2) AU2016323447B2 (es)
BR (1) BR112018004981A2 (es)
CA (1) CA3036652A1 (es)
CO (1) CO2018002703A2 (es)
CY (1) CY1124619T1 (es)
DK (2) DK3350220T3 (es)
EA (1) EA038146B1 (es)
ES (2) ES2881642T3 (es)
FI (1) FI3922645T3 (es)
HR (2) HRP20250666T1 (es)
HU (2) HUE072064T2 (es)
IL (2) IL305148A (es)
LT (2) LT3922645T (es)
MX (5) MX2018003196A (es)
PL (2) PL3922645T3 (es)
PT (2) PT3350220T (es)
RS (2) RS66913B1 (es)
SI (2) SI3922645T1 (es)
SM (2) SMT202100432T1 (es)
WO (1) WO2017049011A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10515A (es) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
WO2009125825A1 (ja) 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
EP4231014A3 (en) 2010-11-30 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
DK2889377T3 (da) 2012-08-24 2020-03-30 Chugai Pharmaceutical Co Ltd Fc?RIIb-Specifik Fc-regionsvariant
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd MOUSE FC RII SPECIFIC FC ANTIBODY
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
JP6706617B2 (ja) 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型−ミオスタチン抗体およびその使用
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
JP7107836B2 (ja) * 2015-09-15 2022-07-27 スカラー ロック インコーポレイテッド 抗プロ／潜在型ミオスタチン抗体およびその使用
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
CN109071645A (zh) 2016-01-08 2018-12-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
US10946036B2 (en) * 2016-06-13 2021-03-16 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
RU2766112C2 (ru) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Композиция для профилактики или лечения связанных с il-8 заболеваний
WO2018129395A1 (en) * 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
US11155611B2 (en) * 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
SI3677278T1 (sl) 2018-07-11 2022-01-31 Scholar Rock, Inc. Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh
BR112021000353A2 (pt) 2018-07-11 2021-08-03 Scholar Rock, Inc. inibidores de tgfb1 de alta afinidade, isoforma-seletivos, e seus usos
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
CN110429214B (zh) 2019-08-07 2021-12-07 宁德时代新能源科技股份有限公司 二次电池的盖组件及二次电池
BR112022003412A2 (pt) * 2019-08-28 2022-05-24 Chugai Pharmaceutical Co Ltd Anticorpos anti-tgf-beta 1 latente de espécies cruzadas e métodos de uso
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
RU2750267C1 (ru) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата
EP4232151B1 (en) 2020-10-26 2025-10-22 Scholar Rock, Inc. Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
IL309078A (en) 2021-06-23 2024-02-01 Scholar Rock Inc A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in the treatment of metabolic disorders
KR102836354B1 (ko) * 2021-11-25 2025-07-22 (주)네오크레마 근아세포의 증식과 근육세포로의 분화를 촉진하는 신규 펩티드 및 이의 용도
KR102840816B1 (ko) * 2021-11-25 2025-07-31 (주)네오크레마 근아세포의 증식과 근육세포로의 분화를 촉진하는 신규 펩티드 및 이의 용도
AU2023265846A1 (en) 2022-05-04 2024-12-12 Scholar Rock, Inc. Use of myostatin inhibitor for treating spinal muscular atrophy
JP2025534681A (ja) 2022-10-14 2025-10-17 ジェネンテック， インコーポレイテッド 脊髄性筋萎縮症の治療方法
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
EP4676954A1 (en) 2023-03-07 2026-01-14 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0845537A1 (en) 1989-08-18 1998-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992015677A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Process for the development of binding mini-proteins
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH09507829A (ja) 1993-03-19 1997-08-12 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−８
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7566768B1 (en) * 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
JP3545403B2 (ja) 1993-04-22 2004-07-21 スカイファルマ インコーポレイテッド 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
CA2158937C (en) 1993-09-15 2006-01-03 Thomas W. Dubensky, Jr. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
PL186073B1 (pl) 1993-10-25 2003-10-31 Canji Preparat farmaceutyczny, zwłaszcza do terapii genowej
CA2176712C (en) 1993-11-16 2000-05-23 Mantripragada Sankaram Synthetic membrane vesicles with controlled release of encapsulated biologically active substances
EP0772689B1 (en) 1994-05-09 2007-12-19 Oxford Biomedica (UK) Limited Retroviral vectors having a reduced recombination rate
CA2194660C (en) 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
CA2364484A1 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
HUP0204247A3 (en) 2000-01-28 2003-10-28 Novo Nordisk As Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity
KR20120053525A (ko) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
AU2011244851A1 (en) 2000-07-27 2011-11-24 The John Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US8455627B2 (en) 2001-10-05 2013-06-04 Affimed Therapeutics, Ag Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
EP1300419B1 (en) 2001-10-05 2007-06-13 Affimed Therapeutics AG Antibody of human origin for inhibiting thrombocyte aggregation
PL218992B1 (pl) 2002-07-19 2015-02-27 Abbott Biotech Ltd Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
MXPA05002648A (es) 2002-09-16 2005-08-19 Wyeth Corp Activacion de miostatina por metaloproteasa, y metodos para modular la actividad de miostatina.
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
AU2003298816C1 (en) 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
BRPI0418317A (pt) * 2003-12-31 2007-05-02 Schering Plough Ltd vacina de aumento de crescimento à base de epitopo de neutralização
JP2007526337A (ja) 2004-03-02 2007-09-13 アクセルロン ファーマ インコーポレーテッド Ａｌｋ７およびミオスタチン阻害剤ならびにその使用
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
WO2005115439A2 (en) 2004-05-27 2005-12-08 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
EA015534B1 (ru) * 2005-04-25 2011-08-30 Пфайзер Инк. Антитела к миостатину и способы их применения
ES2534760T3 (es) 2005-08-19 2015-04-28 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
CN101277976B (zh) 2005-10-06 2012-04-11 伊莱利利公司 抗肌抑制素抗体
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8067562B2 (en) * 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
WO2007061995A2 (en) 2005-11-21 2007-05-31 Novartis Ag Biomarkers for statin-induced myopathy or rhabdomyolysis
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
CA2693178C (en) 2006-11-29 2018-12-04 Nationwide Children's Hospital, Inc. Myostatin inhibition for enhancing muscle and/or improving muscle function
US8119026B2 (en) 2007-03-30 2012-02-21 Merck Patent Gesellschaft Mit Beschrankter Haftung Birefringent layer with negative optical dispersion
CN101970001A (zh) 2007-06-01 2011-02-09 比奥根艾迪克Ma公司 Cripto结合分子
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
KR101558642B1 (ko) 2009-02-24 2015-10-12 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ｔｇｆ-베타 슈퍼패밀리의 설계자 리간드
LT2424895T (lt) 2009-04-27 2017-12-27 Novartis Ag Kompozicijos ir būdai, skirti raumenų augimo spartinimui
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
FI3904391T3 (fi) 2010-03-10 2024-10-02 Genmab As Monoklonaaliset vasta-aineet c-Met:iä vastaan
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TW201210612A (en) * 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
JP2013537425A (ja) * 2010-08-16 2013-10-03 アムジエン・インコーポレーテツド ミオスタチンに結合するポリペプチド、組成物および方法
US8551892B2 (en) 2011-07-27 2013-10-08 Asm Japan K.K. Method for reducing dielectric constant of film using direct plasma of hydrogen
AU2012335541B2 (en) 2011-11-11 2017-07-06 Duke University Combination drug therapy for the treatment of solid tumors
US20130178454A1 (en) 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
WO2013165972A2 (en) 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
PE20150223A1 (es) 2012-06-15 2015-02-11 Pfizer Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
SG10201704616SA (en) 2012-11-06 2017-07-28 Scholar Rock Inc Compositions and methods for modulating cell signaling
EP3816625B1 (en) * 2013-05-06 2025-09-17 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP2853898B1 (en) 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
WO2015070158A1 (en) 2013-11-11 2015-05-14 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety
WO2015195094A1 (en) 2014-06-17 2015-12-23 Ember Therapeutics, Inc. Anti-activin and nati-myostatin antibodies and methods of using the same
JP6706617B2 (ja) * 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型−ミオスタチン抗体およびその使用
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
JP6877357B2 (ja) 2015-04-15 2021-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法
JP7107836B2 (ja) 2015-09-15 2022-07-27 スカラー ロック インコーポレイテッド 抗プロ／潜在型ミオスタチン抗体およびその使用
CN109071645A (zh) * 2016-01-08 2018-12-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
US10946036B2 (en) 2016-06-13 2021-03-16 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
US11155611B2 (en) 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies

Also Published As

Publication number Publication date
AU2016323447A1 (en) 2018-04-12
AU2023203922A1 (en) 2023-07-13
DK3350220T3 (da) 2021-07-12
SMT202100432T1 (it) 2021-09-14
EA201890712A1 (ru) 2018-09-28
MX2022005202A (es) 2022-05-18
CN113896790A (zh) 2022-01-07
HUE055331T2 (hu) 2021-11-29
JP2024038278A (ja) 2024-03-19
US20210046180A1 (en) 2021-02-18
MX2022005211A (es) 2022-05-18
MX2022005177A (es) 2022-06-08
HK1258267A1 (en) 2019-11-08
HRP20250666T1 (hr) 2025-08-01
EP4461312A3 (en) 2025-01-22
WO2017049011A1 (en) 2017-03-23
MX2022005173A (es) 2022-06-08
AU2016323447B2 (en) 2023-03-30
KR20230155021A (ko) 2023-11-09
KR102773636B1 (ko) 2025-02-27
BR112018004981A2 (pt) 2018-10-09
SI3922645T1 (sl) 2025-07-31
JP2022137183A (ja) 2022-09-21
ES2881642T3 (es) 2021-11-30
JP2018527000A (ja) 2018-09-20
US11439704B2 (en) 2022-09-13
FI3922645T3 (fi) 2025-06-25
JP7418508B2 (ja) 2024-01-19
CN113912718B (zh) 2025-05-20
LT3350220T (lt) 2021-09-27
CA3036652A1 (en) 2017-03-23
RS66913B1 (sr) 2025-07-31
CY1124619T1 (el) 2022-07-22
IL258121B1 (en) 2023-09-01
KR20180049075A (ko) 2018-05-10
EP3350220B1 (en) 2021-05-19
KR102596852B1 (ko) 2023-11-02
CN113896789A (zh) 2022-01-07
HUE072064T2 (hu) 2025-10-28
EP3922645B1 (en) 2025-05-14
JP7785107B2 (ja) 2025-12-12
EP3350220A1 (en) 2018-07-25
RS62330B1 (sr) 2021-10-29
JP7107836B2 (ja) 2022-07-27
CN108350067B (zh) 2021-11-05
KR20250033313A (ko) 2025-03-07
PT3922645T (pt) 2025-05-29
PL3922645T3 (pl) 2025-09-08
MX2018003196A (es) 2019-05-16
EP3922645A1 (en) 2021-12-15
DK3922645T3 (da) 2025-06-16
IL258121B2 (en) 2024-01-01
EA038146B1 (ru) 2021-07-13
HRP20211081T1 (hr) 2021-10-15
PL3350220T3 (pl) 2022-01-03
US20230190929A1 (en) 2023-06-22
CN108350067A (zh) 2018-07-31
US10751413B2 (en) 2020-08-25
ES3030258T3 (en) 2025-06-27
EP4461312A2 (en) 2024-11-13
SI3350220T1 (sl) 2021-12-31
IL258121A (en) 2018-05-31
SMT202500263T1 (it) 2025-09-12
LT3922645T (lt) 2025-06-25
CN113912718A (zh) 2022-01-11
US20180344844A1 (en) 2018-12-06
IL305148A (en) 2023-10-01
PT3350220T (pt) 2021-08-06

Similar Documents

Publication Publication Date Title
CO2018002703A2 (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CO2018005614A2 (es) Anticuerpos que se unen específicamente a pd-1 y sus usos
CL2020002314A1 (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
IL286693A (en) Modulator compounds of the integrated stress pathway, compositions comprising same and uses thereof
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
PL3576788T3 (pl) Kompozycja farmaceutyczna o niskim ph zawierająca konstrukty przeciwciał angażujących komórki t
CO2017013405A2 (es) Anticuerpos anti-pd1
MX2022008781A (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos.
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
CR20170079A (es) Agentes de unión a cd123 y usos de estos
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
SI3294325T1 (sl) Krepitev učinka car-izdelanih t celic s cepljenjem z nukleinsko kislino
MX389703B (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
MX385926B (es) Proteínas de fusión de citoquinas.
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
DK3672631T5 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
AR110040A1 (es) Proteínas de unión biespecíficas
BR112016023040A2 (pt) processo para aumentar a atividade ou toxicidade de um peptídeo